Paul Kim – Principal, Kendall Square Policy Strategies
Paul Kim, a leading FDA attorney and policy expert formerly at both the FDA and the US Congress, discusses the current shifts within the American life sciences and regulatory landscape.…
Address: Tour Franklin
100/101 Quartier Boieldieu
La Défense 8
Tour Franklin 100/101 La Défense 8 Quartier Boieldieu 92042 Paris la Défense Cedex,France
Tel: +33 (01) 70 36 03 00
Web: https://www.cipclub.org/Referentiel/
CIP, in accordance with the 1901 French law of associations, contributes to improved circulation of products and information relating to the Public Healthcare System. It works with manufacturers, pharmacists in hospitals and offices, agents, distributors and other representative organisations.
Paul Kim, a leading FDA attorney and policy expert formerly at both the FDA and the US Congress, discusses the current shifts within the American life sciences and regulatory landscape.…
Gala Díaz Langou, a senior analyst and executive director at Argentina’s premier think tank CIPPEC, assesses the country’s recent transformative journey under President Milei. Drawing on 25 years of institutional…
Carlos Ceinos, President & Co-Founder of Principia, leads a Puerto Rico-based consulting firm focused on automation, MES, project management, and validation for the biopharmaceutical industry. Since 2019, the company has…
Monica Bettencourt-Dias of the Gulbenkian Institute for Science highlights the IGC’s pioneering role in biological sciences, supporting scientists and innovators who have significantly contributed to the field globally for over…
MARBIO, a new vaccine manufacturing joint venture in Morocco, is the result of a partnership between the BAB banking consortium (Bank of Africa, Banque Centrale Populaire, and Attijariwafa Bank), Swedish…
Leveraging his 24-year career in Big Pharma, Howard Lin recently moved to set up healthcare and life science consultancy CL Consultancy in Hong Kong. Lin examines the opportunities and challenges…
Thomas Eldered, CEO of Sweden’s largest CDMO Recipharm, founded the company together with his business partner in 1995. Since becoming a public company in 2014, he highlights how this changed…
Carlos Ceinos, president of Puerto Rican service provider Principia, highlights how his previous experience in big pharma helped him to successfully establish his business, dedicated to providing automation and IT…
Oscar Gaspar, VP of the Confederation of Portuguese Industry (CIP), president of the Portuguese Association of Private Hospitalization and former secretary of state for health (2009-2011), provides an informative insight…
Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities…
Sasho Ganov, general manager at BB–NCIPD (BulBio), explains the role of the company in the national health system as the only state-owned enterprise in Bulgaria as well as shares his…
Anant Atal, head of Latin America for Cipla, discusses how the establishment of offices in Colombia was facilitated by its longstanding history in the country, the multiple initiatives the company…
The Country Head Commercial Business of Cipla Czech Republic reviews the challenges faced since Cipla began Czech operations two years ago, the company’s expertise in the respiratory segment, and how…
Giorgio Bruno, CEO of Recipharm Italy, gives an insight into the success factors of the CDMO, discusses the recent acquisition of Mitim, and explains how this acquisition helps Recipharm not…
Tania Zulu Holt, Associate Principal at McKinsey & Company elaborates on the current pressures on the South African healthcare system, discusses the importance of innovation and emphasizes the need for…
IMS Health helps clients reach the top of the mountain by providing them with the necessary intelligence to take actionable steps. Manuel Voll, Senior Principal for Northern Europe shares his…
The phasing out of fiscal incentives in 2006 has impacted the Puerto Rican economy as well as the life science arena. The president of DDD Group, a company offering fully…
IMS’s top consultant in Turkey discusses the common pattern that companies in Turkey have and must follow to adapt to today’s market, and the importance of heeding market signals, such…
Raul Manlapig, Principal Managing Director of Arup, Philippines, talks about the current rapid growth of the country’s economy, how the company’s sustained presence in many countries around the world provides…
A lot of the opportunities and challenges in the pharma and healthcare sector of Romania depend on the overall Romanian business environment in the first place. How would you assess…
The French President declared that he intended to make France the most welcoming and attractive place for the healthcare industry. Do you think this is possible? Can France be the…
Complementing the Lyon region’s strong industrial footprint is a dense network of hospital facilities, only bettered by Paris on the national level. Across 13 hospitals in the Hospices Civils de…
The Auvergne-Rhône-Alpes region, with Lyon at its heart, is France’s industrial heartland. Hosting over 500,000 manufacturing and manufacturing-related jobs, AURA is also the nation’s top destination the production of biologics,…
European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both…
Lyon’s leading biotechs have caught the eye of global pharma in recent years, with two major acquisitions attesting to the quality and sophistication of the ecosystem and laying a path…
Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s…
Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share…
France and Denmark have a rich history of healthcare collaboration, from basic research to clinical trials, as well as major manufacturing investments. What links these two nations, and what are…
France is considered among the leading rare disease markets worldwide, both scientifically and organisationally. The country has cultivated a fully-fledged supporting ecosystem for rare conditions that is today regarded as…
France’s historical contribution to medical research is almost unparalleled globally, with 13 winners of the annual Nobel Prize for Physiology or Medicine, and even more for Chemistry. Most famously, Louis…
France’s patient advocacy network is one of Europe’s most well-developed and formalised. Patient advocacy groups – including the three featured below – fill in research, care, and support gaps left…
France may have ceded Europe’s top spot for the sheer number of clinical trial starts to Spain in 2023, but it remains one of Europe’s most strategically valuable destinations for…
Valued fifth globally in terms of overall revenues and enjoying year-on-year growth rates exceeding five percent, the French pharma market is undeniably one of the great global life science powerhouses,…
See our Cookie Privacy Policy Here
